Medication-induced osteoporosis: screening and treatment strategies
about
Mind the (treatment) gap: a global perspective on current and future strategies for prevention of fragility fractures.Cost Effectiveness of Gastroprotection with Proton Pump Inhibitors in Older Low-Dose Acetylsalicylic Acid Users in the Netherlands.The unsolved case of "bone-impairing analgesics": the endocrine effects of opioids on bone metabolism.Risk factors for osteoporosis and fragility fractures in patients with systemic lupus erythematosus.Prevalence of Osteoporosis and Its Risk Factors in Men with COPD in Qazvin.Musculoskeletal Health of 40-65 Year Old Males and Females in Kosova and the Impact of N05B, A02B (PPI, H2RA), H02AB and Lifestyle Factors on It.Change of Bone Mineral Density and Relationship to Clinical Parameters in Male Stroke Patients.Drug-induced osteoporosis: from Fuller Albright to aromatase inhibitors.Fracture risk in oral glucocorticoid users: a Bayesian meta-regression leveraging control arms of osteoporosis clinical trials.Relationship between antipsychotic medication, serum prolactin levels and osteoporosis/osteoporotic fractures in patients with schizophrenia: a critical literature review.Acid-Suppressive Therapy and Risk of Infections: Pros and Cons.Risk factors for poor bone health in primary mitochondrial disease.Skeletal complications of rheumatoid arthritis.The epidemiology of wrist fractures in older men: the Osteoporotic Fractures in Men (MrOS) study.Side-Effects of Convulsive Seizures and Anti-Seizure Therapy on Bone in a Rat Model of Epilepsy.Impact of physical exercise in cancer survivors during and after antineoplastic treatments.Evidence of Drug-Nutrient Interactions with Chronic Use of Commonly Prescribed Medications: An Update.Effect of tocotrienol from Bixa orellana (annatto) on bone microstructure, calcium content, and biomechanical strength in a model of male osteoporosis induced by buserelin.
P2860
Q30236007-4302821D-A47B-4843-B9F0-9230106F7027Q33611577-23C8FEA6-B682-4D15-B45C-E7FC3CF703F3Q35284151-6B7FFB0D-803D-4DF4-BDDE-D3368EB8A0A1Q36517231-E5ECA14D-4C98-4D77-8558-119D6BF433FEQ37330132-21C8EA3C-FA73-4A11-8286-D75EE1660FC0Q37470966-40233E37-604A-425B-A1A5-8CC7D59F73E4Q37599951-D089D929-C77D-45C4-83C0-195C272E42ECQ38612952-5F6FC6F4-5499-44BF-9E6C-6778DC86D45FQ38676353-7EF7F716-F460-4A47-B0A2-42B7ACBBD39DQ38778145-C5B931EF-4C9C-4CAA-BA99-04FDF30B34E5Q38865456-E0469AA5-0A1A-495F-83A3-C4CB8B8FB290Q39268878-19913B7F-DBA8-4AB0-9CF5-765758ACFE85Q47805955-21965397-C026-4E89-ACBA-64BB4824B513Q49981360-560A27C8-3D4B-4DE3-A549-CD3A381514B4Q50108681-CFF04955-30EB-444C-8C8E-975CA4E0DD9EQ51732172-18E11BED-621D-478D-8EB2-5B61A5738647Q51761248-8C81FCC4-6DB3-4834-8A16-2634B913D9CCQ55373105-988CD09D-0928-4215-89D2-38C70AC6EC89
P2860
Medication-induced osteoporosis: screening and treatment strategies
description
2014 nî lūn-bûn
@nan
2014 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
name
Medication-induced osteoporosis: screening and treatment strategies
@ast
Medication-induced osteoporosis: screening and treatment strategies
@en
Medication-induced osteoporosis: screening and treatment strategies
@nl
type
label
Medication-induced osteoporosis: screening and treatment strategies
@ast
Medication-induced osteoporosis: screening and treatment strategies
@en
Medication-induced osteoporosis: screening and treatment strategies
@nl
prefLabel
Medication-induced osteoporosis: screening and treatment strategies
@ast
Medication-induced osteoporosis: screening and treatment strategies
@en
Medication-induced osteoporosis: screening and treatment strategies
@nl
P2093
P2860
P356
P1476
Medication-induced osteoporosis: screening and treatment strategies
@en
P2093
Amitha Gona
Keshav Panday
Mary Beth Humphrey
P2860
P304
P356
10.1177/1759720X14546350
P577
2014-10-01T00:00:00Z